Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Side Effects Dampen Neurologists’ Enthusiasm For Novel MS Drugs

Executive Summary

With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development - from the first oral options to infrequently administered biologics - the treatment paradigm for the debilitating disease appears on the cusp of significant change

You may also be interested in...

Novartis Finds FREEDOM From Fingolimod Concerns In Second Phase III, Limits Dose To Play It Safe

FREEDOMS clinical trial show lower levels of cancer than first Phase III trial, but Novartis goes one step further by eliminating the highest dose of its oral MS therapy and thus minimizing the side effects associated with FTY720.

Safety Remains Front-Line Concern For Oral MS Drugs

Two drugs in a race to become the first oral treatment for relapsing forms of multiple sclerosis have high safety hurdles to overcome, obstacles that may knock them both out of the running as first-line treatments.

Genzyme Plays Up Emerging Blood Cancer Business In R&D Review

Genzyme has set its sights on emerging as a hematologic cancers specialist – a strategy made possible by a deal made in March, when it gained full rights to Campath from partner Bayer and brought in two additional blood cancer therapies.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts